Intervention calorie restriction reverses the adverse effects of obesity and advanced age on tumor growth in a mouse model of breast cancer

Dalton M. Craven1, Laura A. Smith1, Michael F. Coleman1, Elaine M. Glenny1, Stephen D. Hursting1,2,3

1. Department of Nutrition, University of North Carolina (UNC), Chapel Hill, NC
2. UNC Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, NC
3. Nutrition Research Institute, UNC, Kannapolis, NC

Abstract # 2575

mice either remained on control or DIO diets (n=15
n=30
(A)

Figure 1. Intermittent Calorie Restriction (ICR) Study Design.

Project Aims and Hypotheses

- **Aim 1**: Determine if ICR decreases mammary tumor burden in mice that are obese, aged, or aged and obese. Hypothesis #1: Weight loss by ICR in mice that are obese, aged, or aged and obese will attenuate increased tumor growth associated with obesity and advanced age.

- **Aim 2**: Assess if ICR attenuates pro-inflammatory immune signaling and tumor immunosuppression in mice that are obese, aged, or aged and obese. Hypothesis #2: ICR will reduce obesity- and advanced age-related systemic pro-inflammatory immune signaling as well as increase CD8+ T cell abundance within the mammary tumor.

Animal Study Design

Figure 1. Intermittent Calorie Restriction (ICR) Study Design.

Project Aims and Hypotheses

- **Aim 1**: Determine if ICR decreases mammary tumor burden in mice that are obese, aged, or aged and obese. Hypothesis #1: Weight loss by ICR in mice that are obese, aged, or aged and obese will attenuate increased tumor growth associated with obesity and advanced age.

- **Aim 2**: Assess if ICR attenuates pro-inflammatory immune signaling and tumor immunosuppression in mice that are obese, aged, or aged and obese. Hypothesis #2: ICR will reduce obesity- and advanced age-related systemic pro-inflammatory immune signaling as well as increase CD8+ T cell abundance within the mammary tumor.

Background

- Breast cancer (BC) is the most commonly diagnosed and second deadliest cancer among women in the United States.

- Advanced age and obesity are two major risk factors for BC mortality in women. In our mouse models of BC, we have demonstrated that both advanced age and obesity accelerate mammary tumor growth.

- Mechanistically, enhanced tumor growth in mice that are obese and advanced aged can be explained, in part, by suppression of antitumor immunity-related gene expression and abundance of CD8+ and CD8+ T cells within the tumor microenvironment.

- Interventions capable of reversing the tumor-promoting effects of advanced age and obesity are needed. Calorie restrictive interventions, such as intermittent calorie restriction (ICR), attenuate aging processes and tumorigenesis and thus could offer a low-cost and accessible approach to cancer treatment in patients that are obese or older in age.

Methods

- Mice were weighed and serum was collected prior to tumor inoculation. At study endpoint, tumors were excised, and tumor mass/volume were measured ex vivo.

- Luminex multiplex chemokine assays were used to determine serum cytokine expression levels (n=12
n=16 per group), which consisted of 14% calorie restriction (CR) 5 days/week induced obesity (DIO, n=30
16 per group), which consisted of 14% calorie restriction (CR) 5 days/week induced obesity (DIO, n=30
A) Young (2 mos, n=46) and aged (12 mos, n=46) cohorts of mice were fed either a low-fat, control (control, n=50-52 per age group) or high-fat, diet-induced obesity (DIO, n=50-52 per age group) diet. After 15 weeks, mice either remained on control or DIO diets (n=15-16 per group), later referred to as baseline diet, or were placed on a 32% ICR regimen (n=30-31 per group), which consisted of 14% calorie restriction (CR) 5 days/week and 70% CR 2 non-consecutive days/week (A).

- 9 weeks of ICR treatment, mice received orthotopic injection of 4x105 BC cells that were monitored until tumor endpoint.

- White adipose, mammary, and spleen samples were collected at study endpoint, frozen, and cut into 5 um-thick sections, which were stained for CD3, CD8, CD4, CD11c, and CD11b and were analyzed using QuPath software’s positive cell detection algorithm, which determines percentage of positively stained cells with anti-CD antibody.

Results

- **Figure 2. ICR significantly reduces body weight in young DIO, aged control, and aged DIO mice.**

- **Figure 3. ICR attenuates E0771 mammary tumor growth in young DIO, aged control, and aged DIO mice.**

- **Figure 4. ICR downregulates immune-modulating cytokine expression compared to relative controls.**

- **Figure 5. ICR intervention in young DIO, aged control, and aged DIO mice alters CD8+ T cell abundance in E0771 tumors.**

Conclusions and Future Directions

- **Conclusions**

  - Our preclinical model demonstrates that ICR is an effective dietary intervention that attenuates accelerated tumor growth associated with advanced age and DIO.

  - ICR altered overall cytokine profiles of young DIO, aged control, and aged DIO mice compared to relative controls. Downregulation of immune-modulating cytokines observed in ICR-fed mice may provide insight into how ICR reverses the adverse effects of advanced age and obesity on tumor growth.

  - In align with cytokine expression, tumors from ICR-fed mice exhibited increased abundance of cytotoxic CD8+ T cells, cells vital for antitumor immunity.

  - These findings suggest that ICR reduces mammary tumor burden via decreased immune-related signaling and increased CD8+ T cell abundance.

Ongoing Analysis

Determine if CD8+ T cell abundance is altered by ICR intervention

Contact information: daltondc@live.unc.edu

Acknowledgements: Thank you to AACR and the Science Education and Career Advancement Committee for awarding me the Undergraduate Scholar Award.

Gordon Studer were performed with support from the UNC Lineberger Animal Studies Core Facility at the University of North Carolina at Chapel Hill. The UNC Lineberger Animal Studies Core is supported in part by the NCI Center Core Support Grant (CA016672) to the UNC Lineberger Comprehensive Cancer Center. We acknowledge the UNC Functional Genomics core for microarray profiling of gene expression and the UNC Pathology research core for IHC staining.


Contact information: daltondc@live.unc.edu